

Enoticumab

Cat. No.:	HY-P99925
CAS No.:	1192578-27-0
Target:	Notch
Pathway:	Neuronal Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human DLL4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively^[1].

REFERENCES

[1]. Kuhnert F, Chen G, Thurston G. Potent anti-tumor activity of blocking stromal DLL4 in ovarian xenograft models[J]. Cancer Research, 2013, 73(8_Supplement): 5091-5091.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA